Savara Inc. · 6 hours ago
Director/Senior Director, Early Access Programs
Maximize your interview chances
BiopharmaBiotechnology
Insider Connection @Savara Inc.
Get 3x more responses when you reach out via email instead of LinkedIn.
Responsibilities
Lead and be responsible for the day-to-day operations of the Early Access Program (EAP), including post-trial access, named patient, and compassionate use. Drive strategy and core decisions through facilitation with the EAP Executive Committee.
Ensure that Subject Matter Experts (SMEs) are incorporated into decision-making as appropriate and that relevant leadership team members are informed/endorse EAP strategies. Develop EAP reporting dashboards and metrics to support transparency and decision-making.
Manage and lead Savara’s strong oversight of external EAP vendor partners and operations to manage timelines and ensure excellent service and experience for HCPs and patients who participate in the EAP.
Provide hands-on execution expertise to guide EAP strategy, operations, and risk management across the organization with key functions including Program Management, Supply Chain/Global Technical Operations, Regulatory Affairs, Quality Assurance, Clinical Development, Clinical Operations, and Finance.
Coordinate with Clinical Operations and Program Management to streamline post-trial access for eligible patients. Collaborate with Program Management, Global Technical Operations, and Regulatory Affairs to fulfill regional and local filing and labeling requirements to ensure smooth transition and initiation of eligible patients.
Shepherd the writing, review, approval, and maintenance of all EAP policies, procedures, and related documents (including regional protocols, ICFs, and IFUs that require update as well as Risk Management documentation and related SOPs). Ensure that all EAP activities are managed in accordance with Savara policies and procedures as well as global and local regulatory jurisdictional laws and regulations.
Respond to inquiries from participating or inquiring HCPs about the EAP including how to apply, register, and order investigational product for eligible patients. Facilitate site review (e.g., IRB review where required), budgeting, and site agreement discussions and negotiations between EAP vendors, sites, HCPs, and internal decision-makers.
Partner with Project Management, Commercial, Market Access, and Patient Services to ensure a comprehensive, integrated plan to transition from EAP to Commercial.
Act as central point of contact/knowledge “hub” for all things related to Savara’s EAP.
Qualification
Find out how your skills align with this job's requirements. If anything seems off, you can easily click on the tags to select or unselect skills to reflect your actual expertise.
Required
Bachelor’s degree required
10+ years of experience in late-stage global drug development
5+ years of broad experience in global early access programs
Expertise in Early Access Programs across regions (US, Europe, AsiaPac)
Understanding of clinical trial and EAP protocols
Strong cross-functional facilitation and leadership skills
Knowledge of regulatory and pharmaceutical industry requirements
Outstanding interpersonal, communication, and relationship-building skills across teams
Proven oral and written communication skills, including experience developing and delivering presentations to executive management
Exceptional attention to detail
Ability to thrive in a fast-paced, dynamic environment
Positive, driven, and energetic, able to roll-up their sleeves to get the job done
Preferred
Other advanced health degree or experience within Clinical Operations or Regulatory Affairs is a plus.
Experience working at a specialty EAP vendor is a plus.
Benefits
Competitive compensation package
Benefits
Retirement
Company
Savara Inc.
Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases.
Funding
Current Stage
Public CompanyTotal Funding
$414.1MKey Investors
Silicon Valley BankBain Capital Life SciencesCystic Fibrosis Foundation
2024-06-28Post Ipo Equity· $100M
2022-04-22Post Ipo Debt· $26.5M
2022-01-01Post Ipo Debt· $26.5M
Recent News
2024-12-17
Business Wire
2024-11-25
Company data provided by crunchbase